Politico, October 28, 2025: Politico predicts FDA will revise black box warnings on hormones for menopause, but it isn’t clear how. NCHR’s Diana Zuckerman explains warnings are needed but require more nuance because the evidence is different for hormone creams compared to pills, and evidence of risks and benefits for pills depend on factors such as the type of hormones and the age, medical history, and other differences in the women.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
Some MAHA Supporters Say CNPV Could Lower FDA Standards
Inside Health Policy, October 23, 2025: Inside Health Policy quotes a MAHA meeting that criticized industry influence over FDA, the impact of user fees, the inappropriate reliance on surrogate endpoints for cancer screening and Alzheimer’s drugs. The Lever FDA report finding that most new drugs are approved on evidence inferior to the FDA’s legal standards. NCHR’s Diana Zuckerman is quoted criticizing the FDA’s new CNVP program that promises extremely fast priority reviews for high-impact drugs.
Read More »Kennedy’s Ties to Ally Leading Vaccine Lawsuits Raise Ethical Concerns
New York Times, Oct. 3, 2025: This NYT investigation shows how RFK Jr’s lawyer and long-time colleague Aaron Siri benefits financially from his influence over RFK and HHS, resulting in vaccine policies and other decisions that harm U.S. patients. NCHR president Diana Zuckerman’s experience is included as an example.
Read More »New Blood Tests for Early Cancer Detection Get Some Love From House Members
MedPage Today, September 18, 2025: This news article describes Energy & Commerce Health Committee hearing on bills that would require Medicare cover Breakthrough devices and controversial Multi-cancer Screening tests. NCHR president Dr. Diana Zuckerman testified, describing the cancer tests as “not ready for prime time” and explaining that the latest research shows they are very inaccurate, with some having a false positive rate over 90%
Read More »FDA Leaders Moving to Abandon Advisory Committee Reviews of Specific New Drugs
STAT News, September 12, 2025: FDA seeks to abandon Advisory Committees for specific drugs and use them for bigger issues says CDER head George Tidmarsh. We point out that Expert Panels are also replacing Advisory Committees with one-sided reviews.
Read More »